The latest move by President Donald Trump to try to implement so-called “Most Favored Nation” drug pricing may be more bark than bite, one group of analysts contends. More: White House threatens to 'deploy every tool in our arsenal' to
read moreMerck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey drugmaker told Fierce Pharma. Word of the dismissals comes two days after Merck revealed a sweeping cost-cutting effort designed to save
read moreIn what has become a trend among European drugmakers presenting second-quarter earnings this week, the leadership at France’s Sanofi says it has little to be concerned about after a 15% tariff on European pharmaceutical shipments to the U.S. materialized over
read moreA year after debuting the “Rare Connections” series with a short film about patients’ experiences with neuromyelitis optica spectrum disorder, AstraZeneca’s rare disease unit is turning the cameras on generalized myasthenia gravis. More: AZ's Alexion spotlights generalized myasthenia gravis for
read more
Four-year treatment slows cognitive decline with consistent safety profile More: Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease Source: News
read moreApplications are now open for a pilot program swapping out 340B providers’ upfront discounts for equivalent post-purchase payments, an approach drugmakers say will reduce duplicate discounts and improve transparency. More: HHS will demo drugmakers' 340B rebate model in limited pilot
read more© 1994 - 2025 B.M. Pharmaceuticals